Dallas, Texas 01/24/2014 (FINANCIALSTRENDS) – Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) updates for the company’s proprietary product line-up, especially for Hepatitis C which is one the chronic conditions of this disease. The milestones, according to Achiilion pharmaceuticals is to ensure that there is one-per-day, ribavirin-free therapy accessible to patients with Hepatitis C, in the chronic condition. The data obtained for the company, which includes the vitro data for ACH-3422 and the safety measures ensuring uridine nucleotide inhibitor for NS5B polymerase.
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) lso aims tathe the clinical activity for its ACH-3102 in the Phase 2 will see quicker results. The company believes that the pan-genotypic as well as second-generation NS5Ainhibitor in Phase 2 will offer better results. The outlook for the company is that all of the HCV compounds will be better performers and achievers going forwards in to 2014. The cash balance for the company at the end of 2013, stood at $150 milllion and is expected to have capital for operations into 2016, by which time the treatment of Chronic Hepatitis C will be completed.
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) has been one of the major pharmaceutical companies which are involved in the production of treatments for diseases which are predominantly infection-based diseases. The company is involved in nearly all the phases of development of therapies for treating infectious diseases. The company has reported that there is an increase in the number of innovative options it now provides for the commercial use in treating infectious diseases.
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) holds market capital of $380.90 million and volume shares of 2,214614. The 52 week high for the company is $10.17 and the 52 week trading low for the company is $2.26. The EPS is -0.63. The trading day range for Achillion Pharmaceuticals for the Jan 23, 2014 has been between $3.28 and $4.05. The stock opened the day at $4.04 and has since recorded a slid downwards by over 0.14.